Nantworks Inc. and Sorrento Therapeutics Inc. have expanded their ongoing collaboration with a deal to discover and develop cancer immunotherapies derived from Sorrento's G-MAB library against Nantworks-identified neoepitopes of tumor-specific antigens drawn from its growing body of genomic and proteomic data.